Trexquant Investment LP Acquires 7,811 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

Trexquant Investment LP grew its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIKFree Report) by 15.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,463 shares of the biotechnology company’s stock after buying an additional 7,811 shares during the period. Trexquant Investment LP owned 0.40% of Anika Therapeutics worth $1,325,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Anika Therapeutics by 216.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,393 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 2,320 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Anika Therapeutics by 46.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 13,920 shares of the biotechnology company’s stock worth $259,000 after purchasing an additional 4,410 shares in the last quarter. Jump Financial LLC bought a new position in Anika Therapeutics in the 3rd quarter worth about $652,000. Barclays PLC boosted its stake in Anika Therapeutics by 9.0% in the 3rd quarter. Barclays PLC now owns 26,765 shares of the biotechnology company’s stock worth $499,000 after purchasing an additional 2,209 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Anika Therapeutics in the 3rd quarter worth about $97,000. Institutional investors own 91.53% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIK has been the topic of a number of analyst reports. Stephens reiterated an “equal weight” rating and issued a $22.00 price target on shares of Anika Therapeutics in a research note on Thursday, March 14th. StockNews.com upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. Finally, Barrington Research restated an “outperform” rating and set a $37.00 target price on shares of Anika Therapeutics in a research note on Thursday, May 9th.

View Our Latest Research Report on ANIK

Anika Therapeutics Stock Up 0.8 %

NASDAQ ANIK opened at $24.76 on Wednesday. Anika Therapeutics, Inc. has a 52 week low of $16.54 and a 52 week high of $28.67. The firm has a market capitalization of $367.19 million, a P/E ratio of -4.72, a PEG ratio of 2.28 and a beta of 0.74. The company has a 50-day moving average price of $25.80 and a 200-day moving average price of $24.12.

Anika Therapeutics (NASDAQ:ANIKGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.04). Anika Therapeutics had a negative net margin of 45.39% and a positive return on equity of 0.48%. The business had revenue of $40.52 million for the quarter, compared to analysts’ expectations of $39.23 million. As a group, equities research analysts anticipate that Anika Therapeutics, Inc. will post 1.08 EPS for the current year.

Anika Therapeutics Profile

(Free Report)

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

Read More

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIKFree Report).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.